Antigen presentation by host dendritic cells (DC) is critical for the initiation of adaptive immune responses. We have previously demonstrated in immunogenic routine tumor models that bone marrow (BM)-derived DC pulsed ex vivo with synthetic tumor-associated peptides, naturally expressed by tumor cells, serve as effective antitumor vaccines, protecting animals against an otherwise lethal tumor challenge (Mayordomo, J. I., T. Zorina, W.J. Storkus, C. Celluzzi, L. D. Falo, C.J. Melief, T. lldstad, W. M. Kast, A. B. DeLeo, and M. T. . Nature Med. 1:1297-1302. However, T cell-defined epitopes have not been identified for most human cancers. To explore the utility of this approach in the treatment of tumors expressing as yet uncharacterized epitopes, syngeneic granulocyte/macrophage colony-stimulating factorstimulated and BM-derived DC, pulsed with unfractionated acid-eluted tumor peptides (Storkus, W. J., H.J. Zeh III, R. D. Salter, and M. T. Lotze. 1993.J. lmmunother. 14:94-103) were used to treat mice bearing spontaneous, established tumors. The adoptive transfer of 5 3( 105 tumor peptide-pulsed DC dramatically suppressed the growth ofweaHy immunogenic tumors in day 4 to day 8 established MCA205 (H-2 b) and TS/A (H-2 a) tumor models, when applied in three biweeHy intravenous injections. Using the immunogenic C3 (H-2 b) tumor model in B6 mice, tumor peptide-pulsed DC therapy resulted in the erradication of established d14 tumors and long-term survival in 100% of treated animals. The DC-driven antitumor immune response was primarily cell mediated since the transfer of spleen cells, but not sera, from immunized mice efficiently protected sublethally irradiated naive mice against a subsequent tumor challenge. Furthermore, depletion of either CD4 + or CD8 + T cells from tumor-bearing mice before therapy totally suppressed the therapeutic efficacy of DC pulsed with tumor-derived peptides. Costimulation of the host cell-mediated antitumor immunity was critical since inoculation of the chimeric fusion protein CTLA4-Ig virtually abrogated the therapeutic effects of peptide-pulsed DC in vivo. The analysis of the cytokine pattern in the draining lymph nodes and spleens of tumor-bearing mice immunized with DC pulsed with tumor-eluted peptides revealed a marked upregulation of interleukin (IL) 4 and interferon (IFN) ~/ production, as compared with mice immunized with DC alone or DC pulsed with irrelevant peptides. DCinduced antitumor effects were completely blocked by coadministration of neutralizing monoclonal antibody directed against T helper cell 1-associated cytokines (such as IL-12, tumor necrosis factor or, IFN-~/), and eventually, but not initially, blocked by anti-raiL-4 mAb. Based on these results, we believe that DC pulsed with acid-eluted peptides derived from autologous tumors represents a novel approach to the treatment of established, weaHy imnmnogenic tumors, and serves as a basis for designing clinical trials in cancer patients.
costimulation for effector cell activation, and be targeted to primary, and secondary lymphoid organs rich in naive T cells.
Several reports have previously demonstrated that tumor-specific CTL can be generated that recognize peptide epitopes presented on the tumor cell surface in the context of MHC class I molecules (1) (2) (3) (4) . Tumors, however, have evolved various mechanisms to escape an immune response (1) . Class I or antigen loss variants, secretion of immunosuppressive agents, or lack of costimulation leading to antigen-specific T cell clonal anergy (5) have all been identified. To overcome these states of immunotolerance, cytokine/ costimulatory molecule-engineered tumor vaccines were generated and shown to be capable of eliciting long-term antitumor immune responses in many cases (6) . Effective cytokine gene (i.e., GM-CSF, IL-4, IL-12)-transduced tumor vaccines have been characterized to induce in vivo initial influences of APC, including dendritic cells (DC) l, with subsequent involvement of lymphocytes (7, 8) . For CD4 + T cell priming T cell priming, these APC are likely to ingest tumor Ags for processing and presentation in MHC class II complexes. Presentation of MHC class I-restricted tumor antigens to CD8 § T lymphocytes was classically assumed to be presented by the cell naturally expressing the antigens, such as the tumor cell itself. However, recent evidence suggests that tumor cells are poor APC, and professional APC may be essential for induction of not only CD4 + T cells but also for a CD8 + T cell-mediated antitumot immune response. Huang et al. (9) reported that the in vivo priming of MHC class I-restricted responses involves a transfer of tumor antigens to a host bone marrow-derived DC (BM-DC) and subsequent presentation to CD8 § T cell effectors. Moreover, a correlation between the number of presumptive DC infiltrating a cancer and longer patient survival or reduced frequency of metastatic disease have been observed for a variety, of cancer types (10) . First described by Steinman and Cohn in 1973 (11) , DC have been known to be highly specialized antigen-presenting cells and to be the principal activators of resting, naive T cells in vitro and in vivo (12) (13) (14) (15) , capable of efficiently transporting antigens from the periphery to lymphoid organs. DC pulsed with ovalbumin (16) or viral peptides (17) , lymphoma-derived surface lg (18) , or tumor-derived synthetic epitopes (1a,18a) and then injected as a vaccine have been reproducibly shown to immunize naive animals against a subsequent viral or tumor challenge. Defined tumor-derived T cell epitopes are, however, currently available for study in only a limited number of human tumor types (i.e., melanoma, ovarian, and breast carcinoma [1] ).
To investigate the potential utility of DC-based vaccines for the treatment of cancer patients whose tumors express as yet uncharacterized T cell epitopes, we have evaluated the therapeutic e~cacy ofunfractionated, MHC class I-eluted tumor peptides (19) loaded onto BM-DC as cancer vaccines in murine tumor systems. We show in three different tumor models in two strains of mice that DC pulsed with IAbbreviations used in this paper: BM-DC, bone marrow-derived dendrinc cells; CM, culture medium; DC, dendritic cells; i.d., intradermal.
tumor peptides induced an MHC class I-restricted, T cellmediated antitumor immune response that (a) is capable of markedly suppressing or slowing the growth of established tumors, (b) is completely dependent on costimulatory signals, Thl-associated cytokines, and requires both CD4 + and CD8 + T cells, (c) is Th0-1ike when characterized for the pattern of cytokines elaborated in response to tumor, and (d) confers significantly superior protection when transferred to naive mice if the donor lymphocytes were obtained from mice vaccinated with tumor peptide-pulsed BM-DC coadministered with low doses of malL-12.
Materials and Methods

BM-DC Isolation and Peptide
Pulsing. Culture of BM-DC has been previously described (la, 20). Briefly, lymphocyte-depleted mouse bone marrow suspensions, supplemented with rmGM-CSF + trolL-4 (1,000 IU/ml each, DC media) for 5-8 d leads to the generation of large numbers ('J107/mouse) of functional DC as defined by morphology, ultrastructure, phenotype, and strong mixed lymphocyte reaction~timulating activity. The phenotype of BM-DC typically included high-frequency expression (60--95%) of CD45, CD44, CD11b, CD18, CD80, and CD86, as well as MHC class I and class II antigens. Before use in vaccines, DC were pulsed overnight with crude, acid-eluted tumor peptides from autologous tumors or unfractionated, acid-eluted peptides derived from syngeneic spleens, according to the procedure described below. Peptide-pulsed DC were extensively washed and then irradiated (3,000 rads) before i_v. injection in the tail vein of tumor-bearing animals. In the weakly immunogenic MCA205 and TS/A tumor models, animals were injected three to four times, starting at day 4 or day 8 after tumor establishment and subsequently, every 4 d, with 3-5 • 105 DC pulsed with peptides. Alternatively, in the imnmnogenic C3 tumor model, animals were injected on days 14, 21, and 28 after initial intraderreal (i.d.) tumor inoculation.
Pro~essively growing tumors (MCA205 and C3 in C57BL/6 mice [B6] [H-2bl or TS/A in BALB/c [H-2d]) were surgically removed at day 20-25 ("q50-250 nun 2 in size), and a single-cell suspension was obtained after brief enyzmatic digestion (60 min) with DNase I (0.1 rag/nil; #776785; Boehringer Mannheim Corp., Indianapolis, IN), collagenase (1 mg/ml, 173 U/nag) in AIMV media (GIBCO-B1KL, Gaithersburg, MD). Viable cells ("q-5 X 109/cells) were washed three times in HBSS (Gibco Laboratories), and the cell pellet was treated with mild acid buffer to allow for rapid isolation of tumor-associated peptides, as previously described (19) . Briefly, 10 ml of citrate-phosphate butler, pH = 3.3, was added at room temperature, and cell pellets were immediately resuspended by pipetting and centrifuged for 5 min at 1,000 g. The cell-free supematant was harvested, and peptides in acid-extracted supematants were concentrated on activated SepPak C18 cartridges (Millipore Corp., Bedford, MA). The bound material was eluted with 2-3 ml of 60% acetontrile in water and lyophilized to near complete dryness (i.e., 20-50 Ixl). The peptides were then reconstituted in 1 ml HBSS (GIBCO-BRL) and stored frozen at -20~ until used in DC-pulsing experiments. 1 million BM-DC were pulsed with peptides derived from 10 s to 109 minor cell equivalents ira a total volume of 1-2 nfl of DC media overnight at 37~ 5% CO2.
Tumor Cell Lines and Mouse Strains. Female 6-8-wk-old C57BL/6 (B6) and BALB/c (H-2 d) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). MCA205 (H-2t'), kindly provided b-y ~ S. A. IKosenberg (National Cancer Institute [NCI], Bethesda, MD) is a methylcholanthrene-induced fibrosarcoma established in B6 ,nice. TS/A (H-2 d) is a tumor cell line established by P. Nanni (University of Bologna, Bologna, Italy) from the first in vivo transplant of a moderately differentiated manmlary adenocarcinoma spontaneously arising in a 20-mo-old female BALB/c mouse (21) and kindly provided by G. Fomi (Immunogenetic and Histocompatibility Center, Turin, Italy). The meth A sarcoma is a methylcholanthrene-induced tumor established in H-2 d mice (22). C3 is a tumor cell line obtained by transfecting C57BL/6 mouse embryonal fibroblasts with a plasnfid containing the entire genome of the human papilloma virus type 16 (la). All tumor cell lines were maintained in RPMI-1640 supplemented with 10% fetal bovine serum (Life Technologies, Inc., Grand Island, NY), 2 mM L-glutamine, 100 U/ml penicillin, and 100 pug/ml streptomycin (Whitaker Bioproducts, Walkersville, MD), referred to henceforth as CM (culture medium).
In Vivo Tumor Therapy Models. Twice the nfinimal tumorigenic dose of tumor cells (2 X 10 ~ MCA205, 10 s TS/A, or 2 X 10 ~ C3) were injected i.d. in the right flank of nfice. Animals bearing day 4-to 8-established MCA205 or TS/A tumors were treated with three to tbur biweekly (every 4 d) i.v. injections of 3-5 X 10 s syngenic BM-DC prepared as described above. Animals bearing day 14-established C3 tumors were treated weekly with syngeneic BM-DC (3-5 X l0 s) pulsed with peptide. The mean tumor size was monitored biweekly. All experiments were performed two to three times using individual treatment groups of five mice. Mice were killed when tumors became ulcerated or when they reached a size >250 mm 2.
Depletion Studies with Blockitg Antibodies. CTLA4-Ig, a soluble fusion protein composed of the extracellular domain of the human CTLA4 receptor and the Fc portion of a human IgG1C~ chain has been previously described (23) and was kindly provided by G. Davis (Repligen Corp., Cambridge, MA). 50 pug of CTLA4-IgG1 was admixed with DC-MCA205 or DC-TS/A in vitro, and the mixture was then administered in the tail vein of tumor-bearing animals (three to four injections every 4 d). Mice treated with human IgG (Ganfimmune N, Miles Laboratories, Inc., Elkhart, IN) were used as controls. Hamster nkAbs to mIFN-y (H22) and mTNF-ot (TN3 19.12) were prepared as previously reported (24) . The C17.8 (kindly provided by M. Wysocka [25] , The Wistar Institute, Philadelphia, PA) is an antimp40-IL-12-neutralizing mAb (rat IgG2a), which was administered i.p. (l nag/mouse) 1 h before the first two DC injections. The l lBll (26; rat IgG2a) (hybridoma kindly provided by G. Shearer, NCI) is a neutralizing anti-rolL-4 mAb administered by i.p. injections of 300 ptg/mouse 4 h before and then 24, 48, and 72 h after each of the first two DC injections. Anti-CD4 (clone GK1.5, rat IgG2b) (27) and anti-CD8 (clone 2.43, rat IgG2b) (28) mAb (kindly provided by M. Brunda, Hoffman-La Roche, Nutley, NJ) were injected i.p. on days 2 and 10 (1 nag/mouse/injection) after tumor inoculation. Depletion of CD4 + and CD8 + T cells was monitored by flow cytolnetry. Nomlal rat IgG was administered in negative control groups of animals.
In Vitro Cytokine Release Assays. Retroperitoneal lymph nodes (ipsi-and contralateral from the tumor) and spleens of two nfice per group, in two different experiments, were collected after three to four therapeutic applications (days 16-20). Cells were harvested after mechanical disruption of tissue in a culture dish, counted, and resuspended in CM + 50 IU/ml rhlL-2 (Chiron, Emeryville, CA) at a final concentration of 1. . After a 4-h incubation, 100 gl ofsupernatant was collected, and the percentage of specific S~Cr release was calculated using the following formula: percent 5tCr release = 100 X (cpm experinient -cpm spontaneous release)/(cpm maxinmm release -cpm spontaneous release), where spontaneous release was that obtained from target cells incubated with medium alone, and maximum release was obtained from target cells incubated in 5% Triton X-100 (Sigma Chemical Co., St. Louis, MO). The specificity of tumor-directed cytotoxicity was evaluated by the addition of mAb specific for H-2K b (28-13-35: American Type Culture Collection, Rockville, MD), H-2D b (28-11-55; ATCC), and anti-mCD3 (29B; GIBCO-BRL).
lmmunohistodlemistry. Mice were killed by asphyxiation with CO2 gas. Tissue from tumor sites was removed and placed in a cryomold filled with OCT-embedding medium (Miles Laboratories Inc.). Tissues were snap-frozen by placing the mold on dry ice. Thin sections (5-7 ~m) were cut by cryostat and placed on slides. Slides were stored at -80~ or were immediately stained. Routine hematoxylin-eosin staining was performed on all tissues. Cryostat sections were fixed in cold acetone, hydrated in PBS, and incubated in protein-blocking solution (Inununon; Shandon-Lipshaw, Pittsburgh, PA) for 8 ram. They were then incubated overnight at 40~ with rat mAbs directed against mouse CD4 (TIB207; ATCC) and CD8 (TIB210; ATCC). Isotype-matched rat lgG was used as a negative control. Positive tissue controls consisted of frozen sections of spleens from BALB/c and B6 mice. After buffer washes, endogeneous peroxidase activit 3, was quenched with 0.6% H202 in methanol. Species-absorbed biotinylated mouse anti-rat F(ab')2 (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) was applied to sections incubated with unlabeled prinlary Ab followed by treatment with streptavidin-peroxidase (Boehringer Mannheim Corp.) and 3'-anfino-9-ethylcarbazole (Biomeda Corp., Foster City, CA). Sections were counterstained with hematoxTlin and mounted in CrystalMount (Biomeda Corp.).
Statistical Analyses. Fisher's exact method was performed to interpret the significance of differences between experimental groups (presented as mean + SEM). Significance at 95% confidence limits are presented for individual experiments. Fig. 1 /3) . In a more immunogenic model (i.e., C3), tumors established for 14 d were successfully treated with D C pulsed with unffactionated acid-eluted peptides administered on days 14, 21, and 28. All D C -t u m o r peptide-treated animals exhibited complete and sustained tumor regressions (Fig. 1 C) .
Results
DC Pulsed with Acid-eluted Peptides Derived from Syngeneic Tumors Markedly Inhibits Tumor Progression in Alice Bearing
Coadministration of Low Doses of Systemic rmlL-12 Modulates DC-mediated Antitumor Effects by Enhancing the Memory
Response. Macatonia (Fig. 2 B) .
To verify that D C -M C A 2 0 5 -i n d u c e d antitumor effects stem from the activation of the host immune system and to further evaluate the effects of combined IL-12 administration on the in vivo priming o f T cells, adoptive transfer experiments were performed. Sera and/or spleens were obtained from day 16-18 treatment groups and injected into sublethally irradiated naive littermates. As shown in (Fig. 3, A and B) that  was inhibited 50-60% by anti-H-2K b and H-2D b antibodies or by anti-CD3 (data not shown) . These effector cells did not lyse the murine LAK-sensitive target RMA-S. Splenocytes derived from mice receiving DC-MCA205 + rmlL-12 typically displayed greater cytolytic reactivity than splenocytes from DC-MCA205 alone (Fig. 3 A) . 
hnmmlizations with DC Pulsed with Acid-eluted Peptides Enhance Cytokine Release from the Tumor-draining Lymph Nodes and in the Spleen in Response to
Tumor. Since cellular immunity appeared to be critical in mediating antitumor effects, we analyzed the pattern of cytokines released in an in vitro recall response to MCA205 tumor by ceils derived from the retroperitoneal draining lymph nodes and from the spleens of DC-treated tumor-bearing mice (Table 1) . Freshly isolated mononuclear cells were cultured for 24 h in vitro in the presence of MCA205 rumor. The culture supernatant was then analyzed by ELISA for levels of rolL-4 and mlFN-y production. As expected, a Thl-associated response was observed, with a significant enhancement of mlFN-y production in the DC-MCA205 treatment groups. Interestingly, levels of the Th2-associated cytokine IL-4 were also dramatically elevated in the same groups. In vivo administration of IL-12 did not significantly alter these in vitro results. Similar results were observed for lymphoid cells derived from TS/A tumor-bearing BALB/c mice (Table 2).
Senfiquantitative reverse transcription PeR performed on snap-fi'ozen specimens suggested that DC-MCA205 therapy results in upregulation of messages encoding raiL-4, rolL-5, raiL-10, mlFN-y, and mp40-IL-12 in situ in the nodes of treated mice (data not shown). Interestingly, no discernible qualitative differences in cytokine production were noted between the ipsilateral nodes and their contralateral counterparts. In contrast to the modulation of cytokine messages in the lymphoid organs of DC-MCA205-treated animals, there was no marked difference in cytokines produced in situ within tumor lesions in mice derived from any of the treatment groups. FZetroperitoneal lymph nodes (ipsl-and contralateral from the tumor) and spleens of two mice per group, in two different experiments, were collected after three to four therapeutic applications (days 16-20). Cells were harvested and cocultured vr 10 s irradiated MCA205 (5,000 rads) in 96-well flat-bottomed plates. Plates were incubated for 36 h at 37~ 5% CO 2. The supernatants were harvested and assessed in commericial ELISAs for production ofmlFN-y and raiL-4. Mice bearing day 5 TS/A tumors were treated with DC-based therapies as outlined and reported in To assess the relevance of our in vitro cytokine data (Tables 1 and 2) in the therapy-induced antitumor immune response in vivo, we treated the animals with neutralizing antibodies reactive with T h l -d e r i v e d cytokines (Fig. 4 B) . The coadministration of mAb a n t i -T N F -a and antim l F N -% or anti-raiL-12, completely abrogated D C -M C A 2 0 5 -m e d i a t e d antitumor effects. However, when the first injection o f blocking anti-mlL-12 antibodies was injected after the first immunization with D C -M C A 2 0 5 was performed, the inhibition of therapeutic effects was not significant, stressing the importance of the first vaccination for priming antitumor CTL. Further immunizations may not be critical to amplify the recruitment of additional prime T cells, but perhaps to maintain or expand memory T cells, which are not critically dependent on antigen-specific costimulation. Since high levels o f mlL-4 production were measured in the draining lymph nodes and the spleens of the mice treated with and responding to three to four D C -MCA205 or D C -T S / A peptide immunizations, we investigated whether this Th2-associated cytokine affected the observed antitumor therapeutic response in vivo. The 1 1 B l l (anti-raiL-4) mAb was injected before the first D C -MCA205 injection and on a daily basis thereafter for 8 d. Although tumor volumes were greater in 11B11-treated mice, the difference did not appear significant at day 10 after tumor inoculation, compared with the control group receiving D C -M C A 2 0 5 therapy and injected with normal rat serum (Fig. 4 C) . However, by day 16, the difference started to appear significant at 95% (Fisher's exact method). This suggests that therapy-induced IL-4 may not play a dominant role in the priming of a specific antitumor immune response by the D C -M C A 2 0 5 , but that it may be implicated in maintaining and/or amplifying the induced antitumor immune responses (Tables 1 and 2 ). As previously shown (31), IL-4 can synergize with IL-12 in enhancing the proliferation of antigen-specific T h l clones. In our models, IL-4 may cooperate with coinduced Thl-associated cytokines in promoting antitumor immunity.
Costimulatory Pathways and Th l-associated Cytokines Are
CD8 + T Cells as well as CD4 + T Cells Are Required for the Priming and~or the E ffector Phase of the DC-mediated Antitumor
Immune Response In Vivo. W e have previously demonstrated in our adoptive transfer experiments (Fig. 2 D) that D C -M C A 2 0 5 induced cell-mediated immune response, protecting naive animals from a subsequent MCA205 challenge. Further, DC, arguably the best APC for priming native CD4 + T cells in vivo (11) (12) (13) (14) (15) , elicited potent antitumor CTL responses (Figs. 3, A and / 3) in our in vitro studies. W e next implemented in vivo depletion studies with neutralizing anti-CD4 a n d / o r anti-CD8 antibodies, performed early after tumor inoculation, in order to assess the relative contribution o f CD4 + and CD8 + T cells in the observed therapeutic effects. Both T cell subsets are implicated in D C -M C A 2 0 5 -i n d u c e d antitumor immunity since both anti-CD4 or anti-CD8 antibodies abrogated the antitumor therapeutic response (Fig. 4 D) . The inhibition was significantly greater (Fisher's exact method, at 95%) by day 16, when both anti-CD4 and anti-CD8 antibodies were added, compared with that achieved with either one alone, suggesting a cooperativity between both subsets of T cells in the DC-MCA205-mediated antitumor effects.
hnmunohistochemistry analysis documented a marked perilesional and intratumoral infiltration of CD8 + T cells (and to a lesser extent of CD4 + T cells) at day 16 in the groups treated with DC-MCA205 (data not shown), but not in those treated with DC pulsed with irrelevant peptides.
Discussion
Since Coley's first attempts to design therapeutically relevant tumoricidal cancer vaccines (31a), significant insight into those parameters critical to the induction and maintenance of an antitumor immune response has been gained. The current consensus is that (a) T cells can recognize tumor peptides derived from cellular antigens (1 and la, 2-4, 32), (b) efficient priming of antitumor immune responses results from collaboration of APC and tumor-specific CD4 + and CD8 + T cells, and (c) DC are the most potent APC for priming antigen-specific T cells in vivo and in vitro (11) (12) (13) (14) (15) . Strategically located at sites of antigen exposure, DC efficiently internalize and process/present soluble antigen. This is particularly true for DC progenitors, such as those generated in bone marrow cultures containing GM-CSF (33) (34) (35) .
The concept of using tumor antigen-pulsed APC as a means to elicit antitumor immunity is not novel (1 and la, 36) . DC are ubiquitous in tissue and in blood, but their ex vivo expansion in large numbers has been difficult, until the recent descriptions of methods to generate cultured DC (20, 35, (37) (38) (39) (40) . Previous studies have, indeed, demonstrated the capacity of vaccines to elicit protective antitumor immune responses in naive animals using various forms of tumor antigens and diverse types of normal and transformed APC (18, 18a, 41, 42) . The novelty of the present study is the use of unfractionated, acid-eluted tumor peptides derived from tumors grown in vivo, rather than synthetic peptides, in conjunction with DC grown in IL-4 + GM-CSF (la) to serve as a therapy for established tumors. This protocol may effectively translate into human clinical trials designed to treat patients with diverse tumor histologies.
Although some genes encoding specific tumor-associated antigens recognized by CD8 + T cells have been recently cloned and the relevant antigenic peptides have been identified (la, 2-4), the vast majority of the histologic subtypes of cancers express as yet undefined tumor epitopes. Further, an optimal host antitumor T cell response may require coordinate oligoclonal effector populations for the recognition of a broad spectrum of tumor epitopes rather than responses restricted to a single tumor-associated determinant (la). Given such complexities, we have evaluated whether unfractionated tumor-eluted peptides (containing multiple presumptive T cell epitopes) derived from autologous tumors of different histology and mouse strains can elicit efficient antitumor immunity when presented in vivo by syngeneic BM-DC. We have demonstrated that DC loaded with acid-eluted tumor peptides can drive a Th0-associated immune response in vivo, leading to the suppression of growth of poorly immunogenic tumors.
Although our method for generating tumor-derived epitopes effectively extracts MHC class I-bound peptides from the tumor cells (19) , it is likely that MHC class IIbound tumor peptides or cell-associated proteins may also be eluted. Indeed, each of the tumor cell lines evaluated expressed low to moderate levels of MHC class II when grown in vivo (data not shown). DC priming of class IIrestricted antitumor immune responses is circumstantially supported by our ability to significantly reduce the therapeutic efficacy of DC-MCA20S in tumor-bearing animals by depletion ofCD4 + T cells (Fig. 4 D) . We are currently evaluating the specific impact of affinity-purified MHC class I-and class II-derived tumor peptides in each of our tumor models. Of interest, acid-elution ofpeptides (which does not result in significant cellular lysis) yielded a superior immunogenic source of DC-presented epitopes than peptides extracted frond cells by repeated cycles of freeze-thaw lysis (data not shown). This latter method presumably results in an unsuitably complex mixture ofpeptides that may be further complicated by the release of intracellular proteases. Such peptide complexity would be likely to dilute the effective loading of a sufficient threshold density of relevant T cell epitopes into MHC molecules expressed by DC.
Preliminary studies stress that DC pulsed with specific peptides injected i.v. do not traffic to the tumor itself (36) . Rather, DC injected i.v. localize within the reticuloendothelial system (liver, spleen, and lymph nodes). Indeed, the tumors expressed the same cytokine pattern (IFN-y and IL-10 nflkNA in reverse transcription PCR, data not shown), in effective treatment groups and in control groups. Conversely, in tumor-bearing mice treated with three to four i.v. injections of DC pulsed with acid-eluted tumor peptides, the ipsi-and the contralateral lymph nodes displayed similarly elevated production of both Thl-and Th2-associated cytokines compared with controls, supporting the systemic effects of the DC-based therapy. This result may support a molecular dialogue between DC-T-B cells within lymph nodes involving DC-synthesized cytokines and costimulatory molecules, resulting in the induction of an antitumor immune response.
In vitro data suggest that DC produce IL-12 and direct a Thl imnmne response in naive CD4 + T cells (29) . Further costimulation ofT cells with B7-1, IL-6, and IL-12 (all expressed by DC) is sufficient to generate antigen-specific CTL from naive splenocytes in a mixed lymphocyte tumor culture (43) . We were able to demonstrate a specific class I-restricted cytolytic activity from the spleens of mice vaccinated with DC pulsed with relevant tumor peptides (Fig.  3) , suggesting that a CTL response was elicited by the transfbrred DC in vivo.
The requirements for IL-12 and the B7/CD28 pathway in the therapeutic effects of DC vaccines were supported by our ability to neutralize the effectiveness of therapy by injection of CTLA4-Ig and neutralizing Ab anti-mp40-IL-12 in vivo. IL-12 is a potent inducer of IFN-y and TNF-oL production by both NK cells and T cells (44) . IFN-~/ and TNF-ot are Thl-associated cytokines critically involved in the development of cell-mediated immune response (45) . The neutralization of both cytokines totally abrogates the DC-induced antitumor response. These two cytokines simply account for the role of IL-12 in facilitating the observed immunoreactivity. Interestingly, when the anti-mlL-12 Abs were administered after the first immunization with DC pulsed with the relevant peptides, rather than before the first immunization, the I)C-induced antitumor effects were not significantly affected, suggesting that as few as 5 • 105 DC/mouse can prime a sufficient number of naive T cells to affect tumor growth and that subsequent immunizations may play a role in amplifying or maintaining these "memory" antitumor T cells.
Increases in II,-4 production from draining lymph nodes and spleens were noted in groups of mice receiving three to four in vivo immunizations with DC pulsed with tumor peptides compared with DC pulsed with irrelevant peptides. This observation was not correlated with the size of the tumor but rather with the clinical response to treatment with DC pulsed with the relevant tunmr peptides. Multiple vaccinations of antigen resulted in the progressive development of a Th2-associated response in addition to the Thlassociated immune response elicited during antigen priming. Indeed, the 11Bll neutralizing anti-mIL-4 Abs were not able to significantly block the initiation of a DC peptide-induced antitumor immune response when injected by day 4. The potential immunologic role of a late humoral response cannot be ruled out, however, since the 11Bll reagent eventually significantly inhibited the DC-MCA205-mediated antitumor immune response by day 16.
The antitumor therapeutic efficacy of peptide-pulsed DC was comparable, regardless of the tumor model and the mouse strain examined (C57BL/6 [H-2 b] or BALB/c [H-2d]), and stresses the importance of both CD4 + and CD8 + T cells in the immunity induced by DC pulsed with class I-eluted tumor peptides. Mechanistically, we propose that BM-DC pulsed with tumor peptides migrate to lymph nodes and secrete or induce the secretion of IL-12, thereby driving a CD4 + Thl-associated inn-nune response. Such responses lead to the generation of IFN-y and TNF-c~, as well as, presumably, GM-CSF, IL-3, and other cytokines released by activated Th cells, which in turn may activate other APC in a positive feedback paracrine loop (upregulation of IL-12 and CD80/CD86 after CD40-gp39 ligation [46] ). DC may present class I-eluted peptides directly to CD8 + T cells, which may also be activated after help provided by the DC-primed CD4 + T cells. An enhanced CD8 +, and to a lesser extent, CD4 +, T cell infiltrate was reproducibly found in the peritumoral area as well as inside the tunmr lesion in animals treated with DC pulsed with tumor peptides.
Of note, whereas in vivo antibody neutralization studies clearly support the requirement of IL-12 in the effectiveness of DC-tumor peptide-based therapy, no additional statistically significant advantage was observed with systenfic coadministration of rlL-12, suggesting that DCbased therapies elicit sufficient IL-12 for clinical impact. Alternatively, the dose of systemic rIL-12 that we used may be inappropriate for the observation of any additional therapeutic benefit, a hypothesis that we are currently evaluating. Nognchi et al. (47) studied the influence of IL-12 on p53 peptide vaccination against established meth A sarcoma. They could successfully treat mice bearing established day 7 tumors by immunizing with a specific synthetic tumor peptide plus adjuvant only when IL-12 was coadministered at very low doses (4 ng/mouse/wk) allowing for induction of a specific CTL response. At higher doses, IL-12 suppressed the generation of specific antitumor CTL. Interestingly, in our models, while not reflected in enhanced therapeutic efficacy in situ, an enhanced tumor-specific CTL response could be elicited (Fig. 3 A) , and the immunity transferred to naive animals was more potent when lymphocytes were derived from mice immunized with DC-MCA205 + IL-12 compared with DC-MCA205 alone. Thus, systemic administration of IL-12 appears to positively influence the quality or nature of the resultant cellular immune response. Notably, IL-12 (at the dose used) alone is an efficient antitumor agent in mice bearing early day 4 MCA205 (Fig. 2 A) , whereas in later day 8 tumor models, it has very little effect unless coadministered with DC-MCA205 (Fig. 2 B) .
In summary, 5 • 10 s DC pulsed with acid-eluted tumor peptides significantly impair established tumor growth. The number of DC and the dose of peptides required for optimal therapeutic index remain to be defined. It is possible that the immunogenicity of peptide-pulsed DC may be further augmented by ex vivo culture of DC with cytokines in addition to IL-4 + GM-CSF or upon the engineering of cytokine genes into autologous DC, resulting in the paracrine delivery of cytokines at the site of DC-T-B cell clusters in lymphoid tissues. Systenfic administration of cytokines such as IL-2 may also allow for further dissemination and expansion of tumor-specific T cells elicited by these DC vaccines.
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